The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors

BCR-ABL1-specific tyrosine kinase inhibitors prolong the life of patients with chronic myeloid leukemia (CML) but cannot completely eradicate CML progenitors. The BH3 mimetic, ABT-263, targets prosurvival BCL2 family members, and has activity against CML progenitors. However, the inhibitory effect o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Tun Kiat, Chuah, Charles T.H., Huang, John W.J., Ng, King-Pan, Ong, S. Tiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253416/
https://www.ncbi.nlm.nih.gov/pubmed/25333252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253416/
https://www.ncbi.nlm.nih.gov/pubmed/25333252

Ejemplares similares